Dermata Therapeutics, Inc. (DRMA) stock
DRMANasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.62−0.04 (-6.01%)
Close on Nov 13, 2026Market cap $2.50MP/E –Yield –
Dermata Therapeutics cash
Cash and short-term investments held at the end of each period.
Dermata Therapeutics's cash was $4.82M at Sep 30, 2026. For fiscal 2025 it was $7.52M, up 137.9% from the year before. The highest annual figure on record is $10.80M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.52M | +137.9% |
| FY2024 | Dec 31, 2024 | $3.16M | -57.5% |
| FY2023 | Dec 31, 2023 | $7.44M | +19.2% |
| FY2022 | Dec 31, 2022 | $6.24M | -42.2% |
| FY2021 | Dec 31, 2021 | $10.80M | +1936.0% |
| FY2020 | Dec 31, 2020 | $530.40K | -73.4% |
| FY2019 | Dec 31, 2019 | $1.99M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $4.82M | +3.4% |
| Q2 FY2026 | Jun 30, 2026 | $4.41M | -31.9% |
| Q1 FY2026 | Mar 31, 2026 | $6.95M | -28.5% |
| Q4 FY2025 | Dec 31, 2025 | $7.52M | +137.9% |
| Q3 FY2025 | Sep 30, 2025 | $4.66M | -24.1% |
| Q2 FY2025 | Jun 30, 2025 | $6.48M | +31.0% |
| Q1 FY2025 | Mar 31, 2025 | $9.72M | +105.3% |
| Q4 FY2024 | Dec 31, 2024 | $3.16M | -57.5% |
| Q3 FY2024 | Sep 30, 2024 | $6.14M | -7.4% |
| Q2 FY2024 | Jun 30, 2024 | $4.95M | -41.4% |
| Q1 FY2024 | Mar 31, 2024 | $4.73M | -46.0% |
| Q4 FY2023 | Dec 31, 2023 | $7.44M | +19.2% |
| Q3 FY2023 | Sep 30, 2023 | $6.63M | -17.8% |
| Q2 FY2023 | Jun 30, 2023 | $8.44M | -20.6% |
| Q1 FY2023 | Mar 31, 2023 | $8.77M | +7.0% |
| Q4 FY2022 | Dec 31, 2022 | $6.24M | -42.2% |
| Q3 FY2022 | Sep 30, 2022 | $8.07M | -36.0% |
| Q2 FY2022 | Jun 30, 2022 | $10.63M | +2387.8% |
| Q1 FY2022 | Mar 31, 2022 | $8.19M | +515.7% |
| Q4 FY2021 | Dec 31, 2021 | $10.80M | +1936.0% |
| Q3 FY2021 | Sep 30, 2021 | $12.60M | +1573.6% |
| Q2 FY2021 | Jun 30, 2021 | $427.20K | -42.0% |
| Q1 FY2021 | Mar 31, 2021 | $1.33M | -33.2% |
| Q4 FY2020 | Dec 31, 2020 | $530.40K | – |
| Q3 FY2020 | Sep 30, 2020 | $753.05K | – |
| Q2 FY2020 | Jun 30, 2020 | $736.70K | – |
| Q4 FY2019 | Dec 31, 2019 | $1.99M | – |
See a number that looks wrong?